The pathomechanisms underlying Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 14, Issue 2, 2014, Pages 199-215

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

basal ganglia organization; clinico pathological subtypes; motor and nonmotor symptoms; nigrostriatal dopaminergic system; pathomechanisms of Parkinson's disease; pathophysiology

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; MUSCARINIC RECEPTOR;

AKINESIA; AUTONOMIC NEUROPATHY; BASAL GANGLION; BODY POSTURE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DOPAMINERGIC SYSTEM; DYSKINESIA; GENE MUTATION; HUMAN; HYPOSMIA; LEWY BODY; MORPHOLOGY; MUSCLE RIGIDITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRESYNAPTIC MEMBRANE; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; STRIATONIGRAL DEGENERATION; SYNAPSE; TREMOR;

ALPHA-SYNUCLEIN; BRAIN; HUMANS; LEWY BODIES; PARKINSON DISEASE; PROTEOSTASIS DEFICIENCIES;

EID: 84893129338     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.877842     Document Type: Review

References (224)

1. Jellinger KA. Neurobiology of cognitive impairment in Parkinson's disease. Expert Rev Neurother 2012;12:1451-66
2. Jellinger KA. Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Mov Disord 2012;27:8-30
3. Jellinger KA. Neurobiology of non-motor symptoms in Parkinson disease. J Neurol Disord Stroke 2013;2:1031
4. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 2012;27: 597-607
5. Jellinger KA. The role of alpha-synuclein in neurodegeneration - An update. Translat Neurosci 2012;3:75-122
6. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40
7. Lue L-F, Walker DG, Adler CH, et al. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-Type synucleinopathies. Brain Pathol 2012;22:745-56
8. Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol 2013;47:495-508
9. Kanazawa T, Adachi E, Orimo S, et al. Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol 2012;22:67-78
10. Tanji K, Mori F, Mimura J, et al. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol 2010;120:145-54
11. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010;120:131-43
12. Chu Y, Morfini GA, Langhamer LB, et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012;135: 2058-73
13. Lundblad M, Decressac M, Mattsson B, Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 2012;109:3213-19
14. Yasuda T, Nakata Y, Mochizuki H. Alpha-synuclein and neuronal cell death. Mol Neurobiol 2013;47:466-83
15. Yasuda T, Nakata Y, Choong CJ, Mochizuki H. Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener 2013;2:16
16. Walker DG, Lue LF, Adler CH, et al. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-Type histopathology in human brains. Exp Neurol 2013;240: 190-204
17. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord 2011;26: 1042-8
18. Jellinger KA. Synuclein and Parkinson's disease: An update. In: Martinez A, Gil C, editors. Emerging drugs and targets for Parkinson's disease. The Royal Society of Chemistry; London, UK: 2013. p. 175-214
19. Kumar KR, Lohmann K, Klein C. Genetics of Parkinson disease and other movement disorders. Curr Opin Neurol 2012;25: 466-74
20. Fujioka S, Wszolek ZK. Update on genetics of parkinsonism. Neurodegener Dis 2012;10:257-60
21. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012;124:325-38
22. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27: 831-42
23. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011;26:1049-55
24. Mullin S, Schapira A. Alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol 2013;47:587-97
25. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a009423
26. Freestone PS, Chung KK, Guatteo E, et al. Acute action of rotenone on nigral dopaminergic neurons - involvement of reactive oxygen species and disruption of Ca homeostasis. Eur J Neurosci 2009;30: 1849-59
27. Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 2013;136:2077-97
28. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008;131: 1969-78
29. Janda E, Isidoro C, Carresi C, Mollace V. Defective autophagy in Parkinson's disease: Role of oxidative stress. Mol Neurobiol 2012;46:639-61
30. Guerrero E, Vasudevaraju P, Hegde ML, et al. Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: Implications for Parkinson's disease. Mol Neurobiol 2013;47:525-36
31. Gu G, Reyes PE, Golden GT, et al. Mitochondrial DNA deletions/ rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 2002;61:634-9
32. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. EMBO J 2012;31:3038-62
33. Schapira AH, Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Parkinsons Dis 2011;2011:159160
34. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010;15:1336-53
35. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009;1792:651-63
36. Schon EA, Przedborski S. Mitochondria: The next (neurode)generation. Neuron 2011;70: 1033-53
37. Coskun P, Wyrembak J, Schriner SE, et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 2012;1820:553-64
38. Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol 2012;123:157-71
39. McCoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal 2012;16: 869-82
40. Pilsl A, Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: Emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol 2012;123:173-88
41. Pathak D, Berthet A, Nakamura K. Energy failure: Does it contribute to neurodegeneration? Ann Neurol 2013;74: 506-16
42. Zhou ZD, Lan YH, Tan EK, Lim TM. Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: Implications for iron-related dopaminergic neuron degeneration. Free Radic Biol Med 2010;49:1856-71
43. Lv Z, Jiang H, Xu H, et al. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 2011;118:361-9
44. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011;118:939-57
45. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 2009;16: 879-95
46. Beyer K, Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol 2013;47: 509-24
47. Dimant H, Kalia SK, Kalia LV, et al. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun 2013;1(1):6
48. Angot E, Steiner JA, Lema Tome CM, et al. Alpha-Synuclein cell-To-cell transfer and seeding in grafted dopaminergic neurons In vivo. PLoS ONE 2012;7:e39465
49. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010;11:301-7
50. Lema Tomé CM, Tyson T, Rey NL, et al. Inflammation and alpha-synuclein's prionlike behavior in Parkinson's disease-is there a link Mol Neurobiol 2013;47:561-74
51. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010;37:510-18
52. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Mov Disord 2013;28:24-30
53. Castano JG, González C, Obeso JA, Rodriguez M. Molecular pathogenesis and pathophysiology of Parkinson's disease: New targets for new therapies. In: Martinez A, Gil C, editors. Emerging drugs and targets for Parkinson's Disease. RSC Publishing; London, UK: 2013. p. 26-57
54. Freundt EC, Maynard N, Clancy EK, et al. Neuron-To-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 2012;72:517-24
55. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012;209:975-86
56. Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012;73:1204-15
57. Rey NL, Petit GH, Bousset L, et al. Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013;126:555-73
58. Visanji NP, Brooks PL, Hazrati L-N, Lang AE. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun 2013;1(1):2
59. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14: 153-97
60. Benarroch EE, Schmeichel AM, Low PA, et al. Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain 2005;128:338-44
61. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. Brain 2007;130:469-75
62. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702
63. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130:1577-85
64. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study. Neurobiol Dis 2010;40:216-21
65. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130:1586-95
66. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011;95:163-212
67. Braak H, Sastre M, Bohl JR, et al. Parkinson's disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421-9
68. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009;201:1-119
69. Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol 2012;124:643-64
70. Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70: 1916-25
71. Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008;67: 945-53
72. Orimo S, Uchihara T, Nakamura A, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008;131:642-50
73. Wakabayashi K, Mori F, Tanji K, et al. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 2010;120:1-12
74. Mu L, Sobotka S, Chen J, et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 2013;72: 119-29
75. Phillips RJ, Walter GC, Wilder SL, et al. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic pathway implicated in Parkinson's disease? Neuroscience 2008;153: 733-50
76. Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Mov Disord 2009;24:793-800
77. Amino T, Orimo S, Itoh Y, et al. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005;15: 29-34
78. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007;17: 24-30
79. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009;132:1128-45
80. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 2013;72:130-6
81. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-13
82. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187-204
83. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease - clinical and pathologic features. Mov Disord 2011;26:1015-21
84. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117: 613-34
85. Oinas M, Paetau A, Myllykangas L, et al. Alpha-Synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: A population-based Vantaa 85+ study. Acta Neuropathol 2010;119:715-22
86. Mu L, Sobotka S, Chen J, et al. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 2013;72:614-23
87. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-15
88. Derkinderen P, Rouaud T, Lebouvier T, et al. Parkinson disease: The enteric nervous system spills its guts. Neurology 2011;77: 1761-7
89. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: Prevalence and occurrence before motor symptoms. J Neurol 2013;260:1332-8
90. Annerino DM, Arshad S, Taylor GM, et al. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 2012;124: 665-80
91. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008;65: 1074-80
92. Dickson DW, Fujishiro H, Delledonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115: 437-44
93. Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: An anatomical study. Acta Neuropathol 2009;118:777-84
94. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: A dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33: 599-614
95. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010;5:e8762
96. Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:898
97. Pfeiffer RF, Bodis-Wollner I. editors. Parkinson's disease and nonmotor dysfunction. Humana Press; NY, USA: Springer Science; Totowa, NJ, USA: 2013
98. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011;26:775-83
99. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
100. Tolosa E, Santamaria J, Gaig C, Compta Y. Nonmotor aspects of Parkinson's disease. In: Schapira AHV, Lang AET, Fahn S, editors. Movement disorders 4. Saunders-Elsevier; Philadelphia, PA, USA: 2010. p. 229-51
101. Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: The PRIAMO study. J Neurol 2010;257:5-14
102. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: Features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-39
103. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008;23:837-44
104. Rajput AH, Voll A, Rajput ML, et al. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009;73:206-12
105. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord 2012;27:54-60
106. Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson's disease? Expert Rev Neurother 2012;12:673-86
107. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-57
108. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55
109. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715-25
110. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008;64:485-91
111. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010;25: 2493-500
112. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov Disord 2013;28:237-40
113. Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson's disease: Does the peripheral autonomic system become central? Eur J Neurol 2008; 15(Suppl(1):1-4
114. Lebouvier T, Chaumette T, Paillusson S, et al. The second brain and Parkinson's disease. Eur J Neurosci 2009;30:735-41
115. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
116. Braak H, Rub U, Jansen Steur EN, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404-10
117. Grinberg LT, Rueb U, Alho AT, Heinsen H. Brainstem pathology and non-motor symptoms in. PD. J, Neurol Sci 2010;289:81-8
118. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis 2011;2011:708404
119. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010;25(Suppl 1):S78-82
120. Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl 2006(70):99-103
121. Muller CM, de Vos RA, Maurage CA, et al. Staging of sporadic Parkinson disease-related alpha-synuclein pathology: Inter- and intra-rater reliability. J Neuropathol Exp Neurol 2005;64:623-8
122. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009;1792:730-40
123. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/ categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008;115:399-407
124. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32: 284-95
125. Jellinger KA. Formation and development of Lewy pathology: A critical update. J Neurol 2009;256(Suppl 3):270-9
126. Jellinger KA. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 2009;117:215-16. author reply 217-18
127. Zaccai J, Brayne C, McKeith I, et al. Patterns and stages of alphasynucleinopathy: Relevance in a population-based cohort. Neurology 2008;70:1042-8
128. Fujishiro H, Tsuboi Y, Lin WL, et al. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 2008;116:17-24
129. Weintraub D. Psychiatric issues in Parkinson's disease. In: Schapira AHV, Lang AET, Fahn S, editors. Movement Disorders 4. Saunders-Elsevier; Philadelphia, PA, USA: 2010. p. 213-28
130. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 2012;8: 329-39
131. Doty RL. Olfaction in Parkinson's disease and related disorders. Neurobiol Dis 2012;46:527-52
132. Duda JE. Olfactory system pathology as a model of Lewy neurodegenerative disease. J Neurol Sci 2010;289:49-54
133. Hoyles K, Sharma JC. Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: A pragmatic approach. J Neurol 2013;260:2951-8
134. Silveira-Moriyama L, Holton JL, Kingsbury A, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 2009;453:77-80
135. Petrovitch H, Ross GW, Steinhorn SC, et al. AD lesions and infarcts in demented and no-demented Japanese-American men. Ann Neurol 2005;57:98-103
136. Wu X, Yu C, Fan F, et al. Correlation between progressive changes in piriform cortex and olfactory performance in early Parkinson's disease. Eur Neurol 2011;66: 98-105
137. Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorderneurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010;1184: 15-54
138. Iranzo A, Tolosa E. REM sleep behaviour disorder in Parkinson's disease. In: Chaudhuri KR, Tolosa E, Schapira A, Poewe W, editors. Non-motor symptoms of Parkinson's disease. Oxford Univ. Press; Oxford, England, UK: 2009. p. 177-93
139. Kim YK, Yoon IY, Kim JM, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol 2010;17:487-92
140. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72
141. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346: 861-4
142. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010;5:e12728
143. Pouclet H, Lebouvier T, Coron E, et al. Lewy pathology in gastric and duodenal biopsies in Parkinson's Disease. Mov Disord 2012;27:708
144. Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008;115:443-60
145. Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol Dis 2012;46: 565-71
146. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord 2010;25: 2-12
147. Sone M, Yoshida M, Hashizume Y, et al. Alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol 2005;110:19-26
148. Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 2007;66: 354-62
149. Fil A, Cano-de-la-Cuerda R, Munoz-Hellin E, et al. Pain in Parkinson disease: A review of the literature. Parkinsonism Relat Disord 2013; 19(discussion):285-94
150. Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: Evidence from a case-control study. Arch Neurol 2008;65:1191-4
151. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: A neuroanatomical review. Brain Res 2004;1000:40-56
152. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:781-97
153. Defazio G, Tinazzi M, Berardelli A. How pain arises in Parkinson's disease? Eur J Neurol 2013;20:1517-23
154. Dabby R, Djaldetti R, Shahmurov M, et al. Skin biopsy for assessment of autonomic denervation in Parkinson's disease. J Neural Transm 2006;113:1169-76
155. Jellinger KA. The neuropathologic substrate of Parkinson disease dementia. Acta Neuropathol 2010;119:151-3
156. Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol 2009;118:587-98
157. Sonnen JA, Postupna N, Larson EB, et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010;20:654-9
158. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-31
159. Wichmann T, DeLong MR, Guridi J, Obeso JA. Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord 2011;26:1032-41
160. Wu T, Hallett M. The cerebellum in Parkinson's disease. Brain 2013;136: 696-709
161. Helmich RC, Hallett M, Deuschl G, et al. Cerebral causes and consequences of parkinsonian resting tremor: A tale of two circuits? Brain 2012;135:3206-26
162. Helmich RC, Toni I, Deuschl G, Bloem BR. The pathophysiology of essential tremor and Parkinson's tremor. Curr Neurol Neurosci Rep 2013;13:378
163. Ni Z, Pinto AD, Lang AE, Chen R. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol 2010;68:816-24
164. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81
165. Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 1998;21:32-8
166. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: Motor and cognitive circuits. Brain Res Brain Res Rev 2000;31: 236-50
167. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75
168. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-5
169. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250: 1429-32
170. Rommelfanger KS, Wichmann T. Extrastriatal dopaminergic circuits of the Basal Ganglia. Front Neuroanat 2010;4:139
171. Obeso JA, Lanciego JL. Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat 2011;5:39
172. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: Implications for Parkinson's disease. Nat Rev Neurosci 2010;11:760-72
173. Nambu A, Tokuno H, Hamada I, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 2000;84:289-300
174. Tokuno H, Nambu A. Organization of nonprimary motor cortical inputs on pyramidal and nonpyramidal tract neurons of primary motor cortex: An electrophysiological study in the macaque monkey. Cereb Cortex 2000;10:58-68
175. Bagetta V, Ghiglieri V, Sgobio C, et al. Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 2010;38:493-7
176. Calabresi P, Mercuri NB, Di Filippo M. Synaptic plasticity, dopamine and Parkinson's disease: One step ahead. Brain 2009;132:285-7
177. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26:51-8
178. Jellinger KA. Parkinson's disease. In: Dickson DW, Weller RO, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders. 2nd Edition Blackwell Publishing Ltd; Oxford, England, UK: 2011. p. 194-223
179. Rajput AH, Sitte HH, Rajput A, et al. Globus pallidus dopamine and Parkinson motor subtypes: Clinical and brain biochemical correlation. Neurology 2008;70:1403-10
180. Zaja-Milatovic S, Milatovic D, Schantz AM, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545-7
181. Lee FJ, Wang YT, Liu F. Direct receptor cross-Talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine. J Mol Neurosci 2005;26: 245-52
182. West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: Studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002;22:294-304
183. Reetz K, Gaser C, Klein C, et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov Disord 2009;24:99-103
184. Mori F, Tanji K, Zhang H, et al. Alpha-Synuclein pathology in the neostriatum in Parkinson's disease. Acta Neuropathol 2008;115:453-9
185. Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW. Striatal dopaminergic neurons are lost with Parkinson's disease progression. Mov Disord 2006;21:2208-11
186. Baradaran N, Tan SN, Liu A, et al. Parkinson's disease rigidity: Relation to brain connectivity and motor performance. Front Neurol 2013;4:67
187. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-55
188. Elias S, Israel Z, Bergman H. Physiology of Parkinson's disease. In: Hallett M, Poewe W, editors. Therapeutics of Parkinson's disease and other movement disorders. Wiley-Blackwell; Chichester, UK: 2008. p. 25-36
189. Benninger DH, Thees S, Kollias SS, et al. Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 2009;256:256-63
190. Helmich RC, Janssen MJ, Oyen WJ, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol 2011;69:269-81
191. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. Neuroimage 2011;54: 1244-53
192. Hirschmann J, Hartmann CJ, Butz M, et al. A direct relationship between oscillatory subthalamic nucleus-cortex coupling and rest tremor in Parkinson's disease. Brain 2013
193. Desouza RM, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: A need for reappraisal? Ann Neurol 2013;73:565-75
194. Volkmann J. Surgery Parkinson's disease. In: Hallett M, Poewe W, editors. Therapeutics of Parkinson's disease and other movement disorders. Wiley-Blackwell; Chichester, UK: P. 120-43
195. Hallett M, Deuschl G. Are we making progress in the understanding of tremor in Parkinson's disease? Ann Neurol 2010;68: 780-1
196. Eggers C, Kahraman D, Fink GR, et al. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT SPECT. Basal Ganglia 2011;1:34
197. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-10
198. Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007; 13(Suppl 3):S251-8
199. Ito H, Kusaka H, Matsumoto S, Imai T. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 1996;47:1291-9
200. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123(Pt 11):2297-305
201. Picconi B, Bagetta V, Ghiglieri V, et al. Inhibition of phosphodiesterases rescues striatal long-Term depression and reduces levodopa-induced dyskinesia. Brain 2011;134:375-87
202. Picconi B, Paille V, Ghiglieri V, et al. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008;29: 327-35
203. Ding Y, Won L, Britt JP, et al. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci USA 2011;108:840-5
204. Lee J, Zhu WM, Stanic D, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 2008;131: 1574-87
205. Ahmed I, Bose SK, Pavese N, et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011;134:979-86
206. Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: Filling the bench-To-bedside gap. Lancet Neurol 2010;9:1106-17
207. Heremans E, Nieuwboer A, Vercruysse S. Freezing of gait in Parkinson's disease: Where are we now? Curr Neurol Neurosci Rep 2013;13:350
208. Fling BW, Cohen RG, Mancini M, et al. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain 2013;136:2405-18
209. Shine JM, Moustafa AA, Matar E, et al. The role of frontostriatal impairment in freezing of gait in Parkinson's disease. Front Syst Neurosci 2013;7:61
210. Shine JM, Matar E, Ward PB, et al. Freezing of gait in Parkinson's disease is associated with functional decoupling between the cognitive control network and the basal ganglia. Brain 2013
211. Ingham CA, Hood SH, Taggart P, Arbuthnott GW. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J Neurosci 1998;18:4732-43
212. Villalba RM, Lee H, Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-Treated monkeys. Exp Neurol 2009;215:220-7
213. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 2006;9: 251-9
214. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005;132:741-54
215. Wang Z, Kai L, Day M, et al. Dopaminergic control of corticostriatal long-Term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-52
216. Aymerich MS, Barroso-Chinea P, Perez-Manso M, et al. Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur J Neurosci 2006;23:2099-108
217. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000;47: 345-52
218. Pifl C, Bertel O, Schingnitz G, Hornykiewicz O. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl- 1,2,3,6-Tetrahydropyridine (MPTP). Neurochem Int 1990;17:263-70
219. Kim SD, Allen NE, Canning CG, Fung VS pathophysiology and management. CNS Drugs 2013;27:97-112
220. Martinez-Gonzalez C, Bolam JP, Mena-Segovia J. Topographical organization of the pedunculopontine nucleus. Front Neuroanat 2011;5:22
221. Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012;32: 1609-17
222. Muller ML, Albin RL, Kotagal V, et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain 2013;136:3282-9
223. Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012;135:2779-88
224. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009;1792: 643-50